비교리스트

 카트 문의
시장보고서
상품코드
1609996

비알코올성 지방간염 치료 시장 규모, 점유율, 동향 분석 보고서 : 약물별, 단계별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Non-alcoholic Steatohepatitis Treatment Market Size, Share & Trends Analysis Report By Drug (Vitamin E & Pioglitazone, Resmetirom), By Disease Stage, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 110 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

비알코올성 지방간염 치료 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 비알코올성 지방간염(NASH) 치료 시장 규모는 2025-2030년 동안 28.1%의 CAGR을 기록하며 2030년까지 338억 달러에 달할 것으로 예측됩니다. 비알코올성 지방간염 치료 시장은 주로 Novo Nordisk의 오젬픽, Intercept의 오칼리바, Inventiva의 라니피브라놀과 같은 약물의 출시에 의해 주도되고 있습니다.

미충족 수요 시장에는 승인된 치료제의 부재, 높은 질병 부담, 복잡한 진단 절차 등의 요인으로 인해 큰 미충족 수요가 존재합니다. 현재 시장은 피오글리타존, 비타민E 등 적응증 외 약물이 시장을 점유하고 있습니다. 그러나 미충족 수요에 대응하기 위해 주요 시장 진입자들은 NASH 치료를 위한 새로운 치료법을 개발하기 위한 R&D 활동에 많은 투자를 하고 있습니다. 현재 50개 이상의 파이프라인 후보물질이 존재합니다.

예측 기간 중 출시가 예정된 후기 단계의 파이프라인 후보물질로는 Inventiva Pharma의 Lanifibranor, Intercept Pharmaceuticals의 Oveticholic acid, Galmed Pharmaceuticals Ltd.의 Aramchol, Novo Nordisk A/S의 Semaglutide, Madrigal Pharmaceuticals, Inc.의 Resmetirom 등이 있습니다. 이 중 Intercept Pharmaceutical의 오베티콜산(OCA)과 Madrigal Pharmaceuticals, Inc.의 레스메티롬은 가장 주목받고 있는 의약품으로 다른 파이프라인 후보물질보다 비교적 빠른 진입이 기대되고 있습니다.

연구에 따르면 비알코올성 지방간염은 비만과 당뇨병과 밀접한 관련이 있는 것으로 나타났습니다. 연구에 따르면 NASH 환자의 약 80%가 비만인 것으로 나타났습니다. 미국 등에서는 CDC의 최신 2021년 통계에 따르면 비만 유병률이 42 %로 높습니다. 또한 미국, 일본 등 국가는 비알코올성 지방간염의 유병률이 전 세계적으로 가장 높으며, 이들 국가는 비만과 당뇨병에 대한 부담도 큽니다. 이러한 모든 요인들이 예측 기간 동안 NASH 치료제 시장을 활성화시킬 것으로 보입니다.

제약 대기업의 전략적 이니셔티브와 패스트트랙 지정과 같은 규제 당국의 지원 정책은 시장 성장을 더욱 가속화할 것으로 예상되며, 2022년 5월 Pfizer, Inc.의 엘보가스타트/크레사코스타트 병용요법은 패스트트랙 지정을 받았습니다. 이는 비알코올성 지방간염 치료로서 잠재적인 약물 조합 중 하나입니다. 이러한 의약품 지정은 의약품의 임상시험 과정을 촉진합니다.

간 생검은 비알코올성 지방간염 진단의 표준입니다. 이 진단 검사는 침습적이기 때문에 증상이 있는 경우에만 시행할 수 있으며, 그 결과 NASH의 진단율은 전 세계적으로 평균 약 20%에 불과합니다. 비알코올성 지방간염을 진단할 수 있는 비침습적 바이오마커 검사의 부재는 시장 성장을 저해하는 요인으로 작용할 것으로 예상됩니다.

비알코올성 지방간염 치료 시장 보고서 하이라이트

  • 비타민 E와 피오글리타존(적응증 없음)은 2024년 시장 점유율 100%를 차지하는 유일한 기여자입니다. 이는 시장에서 승인된 의약품을 구할 수 없기 때문입니다.
  • 소매 및 전문약국 부문은 2024년 63.8%의 점유율을 차지했습니다. 소매 및 전문 약국은 NASH와 같은 만성질환과 잘 어울리며, 환자들은 주로 재택 의료 환경에 있는 경우가 많습니다.
  • 북미가 전체 NASH 치료 부문 매출을 주도하고 있습니다. 이는 질병에 대한 인식이 높아지고, 의료 시설이 잘 갖추어져 있으며, 다른 지역보다 치료율이 상대적으로 높기 때문으로 분석됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 비알코올성 지방간염 치료 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 상부 시장 전망
    • 관련/부수 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 비알코올성 지방간염 치료 시장 분석 툴
    • 산업 분석 - Porter's Five Forces 분석
    • PESTEL 분석
  • 파이프라인 분석

제4장 비알코올성 지방간염 치료 시장 : 약제별, 추정·동향 분석

  • 부문 대시보드
  • 세계의 비알코올성 지방간염 치료 시장 : 약제 변동 분석
  • 약제별, 매출
  • 기관지확장제
  • 오베티콜산(OCA)
  • Lanifibranor
  • Semaglutide
  • Resmetirom
  • Aramchol
  • Aramchol
  • Cenicriviroc
  • 기타

제5장 비알코올성 지방간염 치료 시장 : 병기별, 추정·동향 분석

  • 부문 대시보드
  • 세계의 비알코올성 지방간염 치료 시장 : 병기 변동 분석
  • 병기별, 매출
  • NASH 스테이지 F0
  • NASH 스테이지 F1
  • NASH 스테이지 F2
  • NASH 스테이지 F3
  • NASH 스테이지 F3

제6장 비알코올성 지방간염 치료 시장 : 유통 채널별, 추정·동향 분석

  • 부문 대시보드
  • 세계의 비알코올성 지방간염 치료 시장 : 유통 채널 변동 분석
  • 유통 채널별, 매출
  • 병원 약국
  • 소매·전문 약국
  • 기타 약국

제7장 비알코올성 지방간염 치료 시장 : 제품, 용도, 최종 용도, 지역별, 추정·동향 분석

  • 지역 대시보드
  • 시장 규모와 예측 동향 분석, 2018-2030년
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 스웨덴
    • 덴마크
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제8장 경쟁 구도

  • 주요 시장 진출 기업의 최근 동향과 영향 분석
  • 기업/경쟁 분류
  • 벤더 상황
    • 주요 기업의 시장 점유율 분석, 2024년
    • Intercept Pharmaceuticals, Inc.
    • Galmed Pharmaceuticals Ltd.
    • Inventiva.
    • AbbVie Inc.
    • Galectin Therapeutics Inc.
    • Madrigal Pharmaceuticals Inc(Madrigal).
    • NGM Biopharmaceuticals, Inc.
    • Novo Nordisk A/S
    • The Bristol-Myers Squibb Company
    • Gilead Sciences, Inc.
ksm 25.01.03

Non-alcoholic Steatohepatitis Treatment Market Growth & Trends:

The global non-alcoholic steatohepatitis treatment market size is expected to reach USD 33.80 billion by 2030, registering a CAGR of 28.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The non-alcoholic steatohepatitis (NASH) treatment market is primarily driven by the launch of drugs such as Novo Nordisk's Ozempic, Intercept's Ocaliva, and Inventiva's lanifibranor, among others.

The NASH treatment market has major unmet needs owing to factors such as the unavailability of approved drugs, high disease burden, and complex diagnostic procedures. Currently, the market is dominated by off-label drugs such as Pioglitazone and Vitamin E. These are widely prescribed drugs in this space globally. However, to address the unmet opportunity, key market players are heavily investing in R&D activities to develop novel therapeutics for NASH treatment. Currently, there are more than 50 pipeline candidates.

Some of the late-stage pipeline candidates expected to launch during the forecast period include Inventiva Pharma's Lanifibranor, Intercept Pharmaceuticals' Obeticholic acid, Galmed Pharmaceuticals Ltd.'s Aramchol, Novo Nordisk A/S's Semaglutide, and Madrigal Pharmaceuticals, Inc.'s Resmetirom. Among these, Intercept Pharmaceuticals's Obeticholic Acid (OCA), and Madrigal Pharmaceuticals, Inc.'s Resmetirom, are the most looked upon drugs and are expected to enter comparatively earlier than other pipeline candidates.

Research studies reveal that non-alcoholic steatohepatitis is strongly associated with obesity and diabetes. Research studies show that around 80% of NASH patients are obese. In countries such as the U.S., the obesity prevalence is as high as 42%, according to the latest 2021 statistics by CDC. In addition, countries such as the U.S. and Japan account for the highest prevalence of non-alcoholic steatohepatitis globally, and these countries also have a high burden of obesity and diabetes. All such factors will fuel the NASH treatment market throughout the forecast period.

Strategic initiatives by pharma giants and supportive regulatory authority policies such as fast track designation are further expected to accelerate the market growth. In May 2022, Pfizer, Inc.'s Ervogastat/Clesacostat Combination therapy received fast track designation. This is one of the potential drug combinations for the treatment of non-alcoholic steatohepatitis. Such drug designation boosts the clinical trial process for drugs.

Liver biopsy is the gold standard for the diagnosis of non-alcoholic steatohepatitis. The invasive nature of this diagnostics test limits its usage to only symptomatic cases, and as a result, the global average diagnostic rate for NASH is around 20%. The unavailability of biomarkers-based non-invasive tests for the diagnosis of non-alcoholic steatohepatitis is expected to impede the market growth.

Non-alcoholic Steatohepatitis Treatment Market Report Highlights:

  • Vitamin E and Pioglitazone (Off-label) acted as the lone contributor with a 100% share of the market in 2024. This can be attributed to the unavailability of approved drugs in the market
  • The retail and specialty pharmacies segment held a share of 63.8% in 2024. Retail and specialty pharmacies are more compatible with chronic diseases such as NASH, where the patients are more commonly associated with homecare settings
  • North America dominated the overall NASH treatment space in terms of revenue. This can be attributed to increased disease awareness, better healthcare facilities, and comparatively higher treatment rate than in other regions

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Disease Stage
    • 1.2.3. Distribution channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug and disease stage outlook
    • 2.2.2. Distribution channel outlook
  • 2.3. Competitive Insights

Chapter 3. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of Non-Alcoholic Steatohepatitis (NASH) disease
      • 3.2.1.2. Rising awareness about disease
      • 3.2.1.3. Robust product pipeline and rising R&D
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Stringent regulations
  • 3.3. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pipeline Analysis

Chapter 4. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Drug Movement Analysis
  • 4.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, By Drug, Revenue (USD Million)
  • 4.4. Bronchodilators
    • 4.4.1. Vitamin E and Pioglitazone market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Obeticholic Acid (OCA)
    • 4.5.1. Obeticholic Acid (OCA) market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6. Lanifibranor
    • 4.6.1. Lanifibranor market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.7. Semaglutide
    • 4.7.1. Semaglutide market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.8. Resmetirom
    • 4.8.1. Resmetirom market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.9. Aramchol
    • 4.9.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.10. Aramchol
    • 4.10.1. Aramchol market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.11. Cenicriviroc
    • 4.11.1. Cenicriviroc market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.12. Other Drugs
    • 4.12.1. Other drugs market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Disease Stage Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Disease Stage Movement Analysis
  • 5.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, By Disease Stage, Revenue (USD Million)
  • 5.4. NASH Stage F0
    • 5.4.1. NASH stage F0 market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. NASH Stage F1
    • 5.5.1. NASH stage F1 market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. NASH Stage F2
    • 5.6.1. NASH stage F2 market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. NASH Stage F3
    • 5.7.1. NASH stage F3 market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.8. NASH Stage F3
    • 5.8.1. NASH stage F3 market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Distribution Channel Movement Analysis
  • 6.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 6.4. Hospitals Pharmacies
    • 6.4.1. Hospitals pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Retail and Specialty Pharmacies
    • 6.5.1. Retail and Specialty Pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Other Pharmacies
    • 6.6.1. Other pharmacies market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Regional Estimates & Trend Analysis By Product, Application, and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company market share analysis, 2024
    • 8.3.2. Intercept Pharmaceuticals, Inc.
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Galmed Pharmaceuticals Ltd.
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Inventiva.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. AbbVie Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Galectin Therapeutics Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Madrigal Pharmaceuticals Inc (Madrigal).
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. NGM Biopharmaceuticals, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Novo Nordisk A/S
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. The Bristol-Myers Squibb Company
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Gilead Sciences, Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제